Sil­ver­back starts to slow­ly edge out of stealth mode — but there’s still plen­ty be­ing kept un­der wraps

Sil­ver­back Ther­a­peu­tics was one of those stealthy biotechs that some tech writ­ers loved to try and track. The com­pa­ny sur­faced when back­ers re­cruit­ed a high pro­file CEO, Er­ic Dob­meier, out of Seat­tle Ge­net­ics’ c-suite. And the Form D mon­ey filed at the SEC made it look even more in­ter­est­ing as they tried to fill in the miss­ing pieces of the puz­zle.

This morn­ing, Sil­ver­back — af­ter get­ting start­ed 2 years ago — is emerg­ing from the mist.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.